Salvage Treatment for Recurrent Oral Cancer
The surgical treatment of recurrent or previously treated malignancies of the oral cavity presents one of the greatest challenges known to the head and neck surgeon and reconstructive oncologist. These problems are faced with unfortunate frequency and bring oft-devastating functional cost along with the very real threat of death from uncontrolled locoregional disease. The “successful” (long-term locoregional control, effective palliation, the occasional cure) treatment of these cases requires technical expertise and judgment known only to the most experienced head and neck surgeon. Despite this, treatment failure is common and humbling.
KeywordsOral Cavity Radiat Oncol Biol Phys Late Toxicity Free Tissue Transfer Oral Tongue
- 3.Machiels J, Haddad RI, Fayette J, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015;16:583–94.CrossRefPubMedGoogle Scholar
- 4.Seiwert TY, Haddad RI, Gupta S, et al. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. J Clin Oncol. 2015;33(Suppl; abstr LBA6008).Google Scholar
- 6.Pajwani L. Nivloumab may be “game-changer” in head & neck cancer. Onc Live. 2016;17(5):33, 03.16.Google Scholar